AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01627327 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fluticasone furoate/vilanterol 100/25mcg
Description: inhalation powder
Study NCT01627327 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: tiotropium bromide 18mcg
Description: inhalation powder
Study NCT04538326 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Exercise
Description: Participants performed stepping movements that were either cued by the investigator or interacted with a video game. There were three video game exercises that all involved stepping in either a repeated or a random pattern that was either self-paced or game paced.
Study NCT04003168 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Human BCMA targeted T Cells Injection
Description: Autologous genetically modified anti-BCMA CAR transduced T cells
Study NCT05450315 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Stride to Survive:An Exercise Guide for Young Adult Cancer Survivors
Study NCT05450315 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Canadian Physical Activity Guidelines
Study NCT03094780 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Quality of life counseling
Description: Will receive quality of life counseling from PI, social workers, and physical therapists
Study NCT03094780 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Video-conference quality of life counseling
Description: Participants may video-conference to other sites to participate in group session dependent on Florida, Northfield and Arizona enrollment
Study NCT01175850 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Drug-Coated Balloon (DCB)
Description: balloon dilatation and provisional stenting with IN.PACT DCB
Study NCT01175850 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: PTA Balloon: Balloon Angioplasty
Description: balloon dilatation and provisional stenting with standard non-coated PTA balloon
Study NCT04020341 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gepotidacin
Description: Gepotidacin will be available as tablets containing 750 mg gepotidacin. Each dose should be taken with water after consumption of food.
Study NCT04020341 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo matching nitrofurantoin
Description: Placebo matching nitrofurantoin will be available as over-encapsulated unit-dose capsules. Each dose should be taken with water after consumption of food.
Study NCT04020341 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nitrofurantoin
Description: Nitrofurantoin will be available as over-encapsulated capsules containing 25 mg nitrofurantoin macrocrystals and 75 mg nitrofurantoin. Each dose should be taken with water after consumption of food.
Study NCT04020341 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo matching gepotidacin
Description: Placebo matching gepotidacin will be available as unit-dose gepotidacin placebo-to-match tablet. Each dose should be taken with water after consumption of food.
Study NCT03036358 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: teledermatology consult
Description: Information from the dermatologic assessment will be entered into the patients chart.
Study NCT03036358 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Routine Care
Description: The dermatologic assessment will occur but not added to the patients medical record. Dermatology may still be consulted but will be at the prerogative of the treating hospitalist.
Study NCT01841346 — intervention group
Intervention type: PROCEDURE
Intervention: Procedure: PCI
Study NCT02077179 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: HIP Program
Description: The entirety of the HIP Program is delivered through an interactive mobile website.~The physical activity portion of the program consists of daily step counting, prescribed aerobic activity, structured strength and toning workouts, and daily stretching. The program was designed by a local trainer, specializing in postnatal exercise, to increase gradually in intensity, while encouraging a more active lifestyle. The program is designed to be completed at home with minimal equipment.~The nutrition portion of the program consists of 16 video tutorials developed by a local Registered Dietitian and weekly diet logs. The video tutorials cover all aspects of healthy eating, from the basics of Canada's Food Guide, to smart snacking, to eating healthy over the holidays.
Study NCT03339323 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: TKA patients do the exercise intervention
Study NCT02351219 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FOLFOXIRI
Study NCT04528069 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ACRYSOF® IQ PanOptix® Toric Trifocal IOL
Description: Single-piece, ultraviolet and blue-light filtering, foldable, multifocal toric IOL intended to provide vision to aphakic subjects at near, intermediate, and distance and to correct pre-existing corneal astigmatism. This device is approved in Australia.
Study NCT04528069 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cataract surgery
Description: Cataract extraction by phacoemulsification, followed by implantation of the IOL per investigator's standard of care and instructions for use
Study NCT04329754 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Cataract surgery
Description: Cataract surgery with implantation of an intraocular lens (IOL)
Study NCT03584932 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: LINK2 Youth Services Navigation Intervention
Description: There will be 6 in-person sessions delivered by a youth services navigator, plus weekly check-in calls after session 2 for a total of six months. As part of the learning sessions, the participant will learn important information about HIV and how to get the most out of his/her HIV care.
Study NCT01137474 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapagliflozin
Description: Oral tablets administered as 2.5, 5, or 10 mg, once daily for up to 12 weeks
Study NCT01137474 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo-matching dapagliflozin
Description: Oral tablets administered as 0 mg once daily for up to 12 weeks
Study NCT02872701 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OTL38 for Injection
Description: Folate analog ligand conjugated with an indole cyanine-like green dye as a solution in vials containing 3 mL at 2 mg/mL
Study NCT02872701 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Near infrared camera imaging system
Description: Near infrared camera imaging system
Study NCT02872701 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endoscopic or Thoracic Surgery
Description: Endoscopic or Thoracic Surgery
Study NCT01616901 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Spontaneous breathing trial
Description: 5 spontaneous breathing trial will be tested by the patients in the same order :~* 7 cm H2O continuous positive airway pressure~* T piece~* 7 cmH2O of pressure support~* 0 cmH20 of pressure support~* 7 cm H2O pressure support ventilation with 7 cmH20 of end expiratory pressure.
Study NCT01416870 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ICI176,334-1
Description: Subject will receive single dose of ICI176,334-1
Study NCT01416870 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Casodex 80 mg tablet
Description: Subject will receive single dose of Casodex 80 mg tablet
Study NCT00253968 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eplivanserin
Description: oral administration
Study NCT00253968 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: oral administration
Study NCT03963674 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Diacutaneous fibrolysis
Description: Diacutaneous fibrolysis over the gastrocnemious muscles
Study NCT00722891 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Purevision Lenses with ReNu Multiplus
Description: Purevision lenses using ReNu Multiplus lens solution for 28 days
Study NCT00722891 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Purevision Lenses with Optifree RepleniSH
Description: Purevision lenses using Optifree RepleniSH lens solution for 28 days
Study NCT00446381 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Macugen (pegaptanib)
Description: Pegaptanib 0.3 mg by intravitreal injection once pre-operatively
Study NCT00446381 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Macugen (Pegaptanib)
Description: Pegaptanib 0.3 mg by intravitreal injection once pre-operatively.
Study NCT03854968 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality control
Description: The performance of the home mechanical ventilator of all patients in the study will be evaluated with a portable device
Study NCT02645981 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Donafenib
Description: Donafenib is an oral multikinase inhibitor with antiproliferative and antiangiogenic effects
Study NCT02645981 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sorafenib
Description: Control
Study NCT00586911 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cystadane
Description: Betaine 20 mg a day or identical placebo for 1 year.
Study NCT00586911 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Identical Placebo
Description: Placebo
Study NCT00447980 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NT-501
Description: High Dose
Study NCT00447980 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NT-501
Description: Low Dose
Study NCT04052204 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: avelumab
Description: Investigational fully human anti-PD-L1 monoclonal antibody
Study NCT04052204 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bempegaldesleukin
Description: Investigational CD122-biased cytokine agonist
Study NCT04052204 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: talazoparib
Description: poly (adenosine diphosphate \[ADP\] ribose) polymerase (PARP) inhibitor
Study NCT04052204 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: enzalutamide
Description: androgen receptor inhibitor
Study NCT03540654 — intervention group
Intervention type: OTHER
Intervention: Budget impact
Description: Budget impact, using a probabilistic markov model, of discontinuing TKI treatment in patients with CML in deep molecular response since at least two years, compared with current practice (treatment during entire life), from the healthcare system point of view
Study NCT03220490 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 5 minute interval between regular glaucoma drops - Long term
Description: In the selected eye, the patient will be asked to take his two regular IOP reduction drugs while keeping a five minute time interval between instillation of the first and second drug for a duration of one month.
Study NCT03220490 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: no interval between regular glaucoma drops - Long term
Description: In the selected eye, the patient will be asked to take his two regular IOP reduction drugs one after the other with no waiting period for a duration of one month.
Study NCT01683253 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levodopa/Carbidopa(200mg/50mg)
Study NCT01683253 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dopaminergic Agonists
Description: Treated for at least 6 months after diagnosis of Parkinson's Disease.
Study NCT03043274 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cangrelor
Description: Cangrelor 30 mcg/kg bolus followed by a 4 mcg/kg/min intravenous infusion prior to PCI will be given. It will be continued for ≥ 2 hours or for the duration of the procedure, whichever is longer.
Study NCT06230120 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Spinal Cord Stimulation
Description: Stimulation electrode tip (Vectris™ SureScan MRI percutaneous lead, Medtronic Inc, Minneapolis, US)~External electrical pulse generator (Wireless External Neurostimulator System (WENS), Medtronic)
Study NCT06230120 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham
Description: Stimulation electrode tip (Vectris™ SureScan MRI percutaneous lead, Medtronic Inc, Minneapolis, US) with external stimulator turned off
Study NCT00814320 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant human hyaluronidase (rHuPH20)+ immune globulin intravenous (IGIV)
Description: Comprises subjects previously participating in Study 160601, who now only complete Study Epoch 2 (subcutaneous \[SC\] infusions) as bioavailability/exposure for intravenous (IV) treatment was already obtained in Study 160601.~Study Epoch 2: Dose (calculated) of rHuPH20 followed by dose (calculated) of IGIV, 10% by SC infusion. Treatment intervals and doses are to be increased as defined, until treatment interval is the same as the pre-study treatment interval for IV treatment (ramp-up).
Study NCT00814320 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant human hyaluronidase (rHuPH20)+ immune globulin intravenous (IGIV)
Description: Comprises all other subjects.~Study Epoch 1: IV infusion of IGIV, 10% (same dose and frequency as pre-study) to determine pharmacokinetics.~Study Epoch 2: Dose (calculated) of rHuPH20 followed by dose (calculated) of IGIV, 10% by SC infusion. Treatment intervals and doses are to be increased as defined, until treatment interval is the same as the pre-study treatment interval for IV treatment (ramp-up).
Study NCT03220490 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IOP reduction of Brimonidine and Timolol with time interval
Description: In the selected eye the subject will be given two types of IOP reduction drops: first Brimonidine, Alphagan® (an alpha-agonist) followed by Timolol, Tiloptic® (a beta-blocker). The drops will be given with a time interval of five minutes between the first and second drop.
Study NCT03220490 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IOP reduction of Brimonidine and Timolol no time interval
Description: In the selected eye the subject will be given two types of IOP reduction drops:first Brimonidine, Alphagan® (an alpha-agonist) followed by Timolol, Tiloptic® (a beta-blocker). The drops will be given one after the other with no waiting period.
Study NCT00696748 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nebido (testosterone undecanoate)
Description: Nebido (testosterone undecanoate) intramuscular 4 ml by scheme
Study NCT00696748 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo 4 mL intramuscular
Study NCT02481544 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Gratitude Journaling Plus SOC
Study NCT02481544 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Memorable Events Journaling Plus SOC
Study NCT01989026 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: BCG
Study NCT04102202 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BOL-DP-o-05
Description: BOL-DP-o-05
Study NCT04102202 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT03520166 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Medium frequency electrotherapy (interferential currents)
Description: Treatment with medium frequency electrotherapy, interferential currents between 5500 Hz and 8500 Hz (Combi-200®, Gymna®), was performed using transvaginal application. The frequency was increased progressively over the first six sessions (twice a week), starting with a frequency of 5500 Hz until reaching a frequency of 8500 Hz, which remained until the end of treatment.
Study NCT03520166 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: No treatment
Description: No treatment
Study NCT02506842 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nab-paclitaxel
Description: Patients firstly receive nab-paclitaxel 100 mg/m\^2 (iv, 30 minutes) on days 1, 8, and 15 for 3 weeks, followed by one week without treatment. Treatment repeats until there is disease progression or recurrence.
Study NCT02506842 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine
Description: Patients secondly receive gemcitabine 1000 mg/m\^2 (iv, 30 minutes) on days 1, 8, and 15 for 3 weeks, followed by one week without treatment. Treatment repeats until there is disease progression or recurrence.
Study NCT02506842 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oxaliplatin
Description: Patients receive oxaliplatin 85 mg/m\^2 (iv, 2 hours) on days 8 and 22 with 42 days as a cycle. Treatment repeats until there is disease progression or recurrence. Oxaliplatin is given before folinic acid and fluorouracil when the three drugs are given on the same days.
Study NCT02506842 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: folinic acid
Description: Patients receive folinic acid 200 mg/m\^2 (iv) on days 1, 8, 15 and 22 for 4 weeks, followed by 2 weeks without treatment. Treatment repeats until there is disease progression or recurrence.
Study NCT02506842 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fluorouracil
Description: Patients receive fluorouracil 2000 mg/m\^2 (iv, 24 hours) on days 1, 8, 15 and 22 for 4 weeks, followed by 2 weeks without treatment. Treatment repeats until there is disease progression or recurrence.
Study NCT04233476 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 99mTc-3PRGD2 injection
Description: A diagnostic drug targeting integrin αvβ3, technetium-99m \[99mTc\] labeled hydrazinonicotinamide-PEG4-E\[PEG4-c(RGDfk)\]2 (99mTc-3PRGD2), will be intravenously injected to the participants for imaging of lung cancer and mapping lymph node metastasis via single photon emission computed tomography/ X-ray computed tomography (SPECT/CT) .
Study NCT02294890 — intervention group
Intervention type: PROCEDURE
Intervention: Total knee arthroplasty
Study NCT03931148 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Geriatric Assesment with neuropsychological test more specific on decision making
Description: The following tests will be made : MoCA, FAB, TMT, Stroop-Victoria, JAT
Study NCT03931148 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Functional RMI
Description: With specific test of decision making (IGT) specially adapted to the population
Study NCT03931148 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: High Resolution EEG
Description: With specific test of decision making (BART) specially adapted to the population
Study NCT03931148 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Qualitative interview
Description: Qualitative semi-directed interviews with participants, their caregivers and their geriatrician to analyse everyday life decision making ability.
Study NCT00758238 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: myBP facilitated e-health self-management
Description: MyOSCAR, a web-based patient-controlled personal health record, provides a mechanism for patients to enter/track health information and can encourage longitudinal patient engagement, better interaction between patients and health care providers, and patient self management. The intervention will provide access via MyOSCAR to a cardiovascular risk profile and BP tracker with sharing to providers enabled. Patients can receive general information about hypertension management; tailored messages related to their modifiable risk factors; and secure messaging with multiple providers. Providers can draw on a 'menu' of links/resources to share with patients. A lifestyle changes planner/checklist and an enhanced medication diary are additional components.
Study NCT03546881 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: fusion imaging guidance technology
Description: Imaging fusion guidance overlay used during PAOD endovascular revascularisation
Study NCT03546881 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: 2D X-ray screen
Description: 2D X-ray screen during PAOD endovascular revascularisation
Study NCT03546881 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: 2D X-ray screen
Description: 2D X-ray screen during PAOD endovascular revascularisation
Study NCT05088070 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SPH 3348
Description: 2 tablets of 8mg SPH3348 will be orally administered once a day with empty stomach
Study NCT05088070 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SPH 3348
Description: 1 tablet of 40mg SPH3348 will be orally administered once a day with empty stomach
Study NCT05088070 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SPH 3348
Description: 2 tablets of 40mg SPH3348 will be orally administered once a day with empty stomach
Study NCT05088070 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SPH 3348
Description: 4 tablets of 40mg SPH3348 will be orally administered once a day with empty stomach
Study NCT05088070 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SPH 3348
Description: 6 tablets of 40mg SPH3348 will be orally administered once a day with empty stomach
Study NCT05088070 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SPH 3348
Description: 8 tablets of 40mg SPH3348 will be orally administered once a day with empty stomach
Study NCT02384759 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: aflibercept
Study NCT02384759 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LV5FU2
Study NCT02384759 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: LV5FU2